Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
Authors
Keywords
-
Journal
Diabetes Therapy
Volume 11, Issue 2, Pages 369-386
Publisher
Springer Science and Business Media LLC
Online
2019-12-21
DOI
10.1007/s13300-019-00747-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
- (2019) Milton Packer et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- GLP-1 Receptor Agonists and Kidney Protection
- (2019) Eulalia Valentina Greco et al. Medicina-Lithuania
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
- (2019) Amar Ali et al. Diabetes Therapy
- Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- (2019) Stefan D. Anker et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study
- (2019) James B. Wetmore et al. BMC Endocrine Disorders
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Effects of Diabetes Medications Targeting the Incretin System on the Kidney
- (2018) Richard J. MacIsaac et al. Clinical Journal of the American Society of Nephrology
- The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
- (2018) Keizo Kanasaki CLINICAL SCIENCE
- Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
- (2018) M. ANGELYN BETHEL et al. DIABETES
- Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
- (2018) Greer Waldrop et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis
- (2018) Samuel Seidu et al. Primary Care Diabetes
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
- (2018) Christopher P. Cannon et al. AMERICAN HEART JOURNAL
- Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
- (2018) Habib Yaribeygi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
- (2017) Ashu Rastogi et al. Diabetes Therapy
- SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
- (2017) Ashu Rastogi et al. Diabetes Therapy
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- SGLT2 Inhibitors and the Diabetic Kidney
- (2016) Paola Fioretto et al. DIABETES CARE
- Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men
- (2016) M. H. A. Muskiet et al. DIABETES OBESITY & METABOLISM
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
- (2016) Lennart Tonneijck et al. DIABETOLOGIA
- Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort
- (2016) Carmen Wolke et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men
- (2015) Ali Asmar et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- (2015) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
- (2013) Jeppe Skov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis
- (2013) H.-Y. Wu et al. BMJ-British Medical Journal
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease
- (2012) Ai-li Sun et al. Diabetes & Vascular Disease Research
- Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs
- (2012) N. Hex et al. DIABETIC MEDICINE
- Risk for ESRD in Type 1 Diabetes Remains High Despite Renoprotection
- (2011) E. T. Rosolowsky et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search